Laureate Pharma Extends its Agreement with Cytogen for Manufacture of PROSTASCINT®

Princeton, NJ - October 25, 2006: Laureate Pharma, Inc. announced today that it has renewed its agreement with Cytogen Corporation for the cGMP manufacture of ProstaScint®, Cytogen's proprietary monoclonal antibody immunoconjugate that is used for imaging in patients diagnosed with prostate cancer. Under the agreement, Laureate will provide cGMP protein production, purification, conjugation of Cytogen's proprietary linker chelator and aseptic filling services to support Cytogen's commercial ProstaScint® requirements. Terms of the agreement were not disclosed.

"We are delighted by the confidence that Cytogen has shown in Laureate by continuing to utilize our specialized experience in the manufacture of ProstaScint®," said Robert J. Broeze, President & CEO of Laureate. "We have developed a great working relationship with our colleagues at Cytogen and we look forward to helping them achieve their manufacturing objectives."

ProstaScint® has been manufactured in Laureate's cGMP manufacturing facility in Princeton, NJ for more than 10 years.

About Laureate Pharma

Laureate Pharma, a full service biopharmaceutical development and protein production company, located in Princeton, NJ offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit www.laureatepharma.com. Laureate Pharma, Inc. is a partner company of Safeguard Scientifics, Inc. (NYSE: SFE; www.safeguard.com.), which builds value in high-growth, revenue stage information technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operational and management resources to its partner companies.